The facility, which is expected to start operations in 2017, will manufacture about 40 million packs and 850 million tablets of around 30 medicines every year.
It represents over 60% of the medicines sold in Russia by AstraZeneca.
Other pharmaceutical companies such as Pfizer, Sanofi, Novartis and Novo Nordisk have also unveiled plans to increase investment in production and research in Russia.
AstraZeneca CEO Pascal Soriot said: "Our new dedicated production facility will support our efforts to bring innovative medicines from our exciting pipeline to patients in Russia.
"This opening builds on our investments in clinical research and scientific collaborations in this important country and serves to reinforce our long term commitment to Russia."
AstraZeneca currently employs over 1,400 people in Russia working across commercial, manufacturing, scientific and clinical research and enabling functions.
About 50 of the company’s medicines are licensed for sale in Russia.
The new plant expands AstraZeneca’s worldwide manufacturing capabilities to support its portfolio of medicines and increasing demand.
Earlier this year, AstraZeneca acquired a new site in Boulder, Colorado, US, and unveiled biologics manufacturing investments in Sweden.
Image: AstraZeneca executive director and CEO Pascal Soriot. Photo: courtesy of AstraZeneca.